| Company* (Country; Symbol) | Product | Description | Indication | Status (Date) |
| AUTOIMMUNE | ||||
| Chelsea Therapeutics International Ltd. (CHTP) | CH-1504 | A nonmetabolized antifolate designed to avoid the kidney and liver toxicities associated with methotrexate | Rheumatoid arthritis | Started a Phase II trial (1/23) |
| CollaGenex Pharmaceuticals Inc. (CGPI) | Becocalcidiol | A vitamin D analogue | Psoriasis | Started a Phase II trial (1/14) |
| CollaGenex Pharmaceuticals Inc. (CGPI) | Oracea | A delayed-release formulation of doxycycline | Rosacea | Phase II showed that 100 mg of doxycycline did not provide a greater clinical benefit than Oracea at 40 mg, but had more adverse events (1/17) |
| Incyte Corp. (INCY) | INCB18424 | An oral JAK inhibitor | Rheumatoid arthritis | Phase IIa data showed three of four patients achieved ACR50 criteria (1/8) |
| CANCER | ||||
| Affymax Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (Japan) | Hematide | Synthetic, peptide-based erythropoiesis stimulating agent | Anemia in cancer patients | Dosed the first patient in a 100-patient clinical trial (1/25) |
| Allos Therapeutics Inc. (ALTH) | PDX | Pralatrexate | Advanced non-small-cell lung cancer | Initiated a Phase IIb trial (1/7) |
| Celgene Corp. (CELG) | Revlimid | Lenalidomide | Multiple myeloma | Revlimid plus dexamethasone and Biaxin had an overall response rate of 90.3% (1/4) |
| Cell Therapeutics Inc. (CTIC) | Zevalin (FDA-approved) | Ibritumomab tiuxetan | Non-follicular indolent non-Hodgkin's lymphoma | Phase II data showed the addition of Zevalin to chemotherapy was well tolerated and effective, producing a 100% complete remission at the end of treatment (1/22) |
| Cyclacel Pharmaceuticals Inc. (CYCC) | Sapacitabine | An oral nucleoside analogue | Acute myeloid leukemia | Initiated an open-label, randomized, Phase II trial (1/2) |
| EntreMed Inc. (ENMD) | MKC-1 | A cell cycle inhibitor | Recurrent or resistant epithelial ovarian cancer | Started a Phase II study (1/23) |
| EntreMed Inc. (ENMD) | Panzem NCD | 2-methoxyestradiol | Advanced or metastatic carcinoid tumors | Phase II interim results of Panzem NCD in combination with Avastin showed that 27 of 29 patients had stable disease and two had progressive disease (1/28) |
| Immunotec Inc. (Canada; CDNX: IMM) | IMN 1207 | A glutathione-enhancing cysteine-rich whey protein isolate | Cachexia in lung cancer patients | Completed a 66-patient trial, demonstrating a significant increase in body weight (1/17) |
| Kosan Biosciences Inc. (KOSN) | Alvespimycin | Second-generation Hsp90 inhibitor | HER2-positive metastatic breast cancer | Started a Phase II trial (1/15) |
| Maxygen Inc. (MAXY) | MAXY-G34 | Recombinant version of granulocyte colony stimulating factor | Breast cancer | Phase II patients met the safety criteria with no serious adverse events or immunogenicity (1/7) |
| MethylGene Inc. (Canada; TSX:MYG) and Pharmion Corp. (PHRM) | MGCD0103 | An isotype-selective histone deacetylase inhibitor | Relapsed or refractory Hodgkin's lymphoma or non-Hodgkin's lymphoma | Enrolled the first patient in a Phase II trial (1/9) |
| Morphotek Inc. (subsidiary of Eisai Co. Ltd.; FSE:EII) | MORAb-009 | Inhibits mesothelin, a cell surface protein | Pancreatic cancer | Started a Phase II trial (1/7) |
| Nektar Therapeutics Inc. (NKTR) | NKTR-102 | PEG-irinotecan; uses small-molecule PEGylation platform | Colorectal cancer | Started a Phase II program (1/8) |
| Neose Technologies Inc. (NTEC) | NE-180 | Erythropoiesis-stimulating agent (ESA); glycoPEGylated erythropoietin | Anemia in cancer | Neose is discontinuing development due to a lack of partnering interest (1/30) |
| Pro-Pharmaceuticals Inc. (AMEX:PRW) | Davanat | A carbohydrate polymer composed of mannose and galactose | Colorectal cancer | Phase II data showed it improves median progression-free survival (1/29) |
| Protherics plc (UK; PTIL) | OncoGel | A locally administered sustained-release formulation of paclitaxel | Esophageal cancer | Enrolled the first patient in a Phase IIb study (1/24) |
| pSivida Ltd. (Australia; PSDV) | BrachySil | A combination of BioSilicon and the isotope phosphorus | Pancreatic cancer | Phase IIa results showed that BrachySil in combination with gemcitabine was well tolerated with no clinically significant adverse events (1/28) |
| Threshold Pharmaceuticals Inc. (THLD) | Glufosfamide | Small molecule targeting abnormal glucose metabolism | Soft tissue sarcoma | Phase II data showed clinical activity but indicated a need for a different dosing regimen to improve the therapeutic index (1/18) |
| Transgene SA (France; PARIS:TNG) | TG4010 | MVA-MUC1-IL2; uses modified vaccinia ankara virus vector and expresses the entire MUC1 gene sequence | Non-small-cell lung cancer | Phase IIb data confirmed the favorable safety profile of the drug when associated with chemotherapy (1/10) |
| ZymoGenetics Inc. (ZGEN) | IL-21 | Recombinant Interleukin 21 | Renal cell cancer | Started a Phase II trial (1/8) |
| CARDIOVASCULAR | ||||
| Anthera Pharmaceuticals Inc.* | A-002 | An inhibitor of secretory phospholipase A2 | Cardiovascular disease | Second Phase IIb data showed it lowered both secretory phospholipase A2 and LDL-C levels (1/15) |
| Chelsea Therapeutics International Ltd. (CHTP) | Droxidopa | An orally active synthetic precursor of norepinephrine | Intradialytic hypotension | Started a Phase II trial (1/7) |
| Corthera Inc.* | Relaxin | Naturally occurring peptide hormone that acts as a targeted vasodilator with systemic and renal hemo-dynamic effects | Acute heart failure | Started a Phase II trial (1/8) |
| DeCODE Genetics (Iceland; DCGN) | DG051 | A leukotriene A4 hydrolase inhibitor | Heart attack and coronary artery disease | Phase IIa confirmed it delivers significant dose-dependent reductions in leukotriene B4 (1/9) |
| Karo Bio AB (Sweden; SSE:KARO) | KB2115 | Eprotirome | To lower cholesterol | Phase IIb data showed it lowered blood cholesterol levels by up to 40% without negative effects on the heart (1/17) |
| Surface Logix* | SLx-2101 | An oral, selective, fast-onset, long-acting PDE5 inhibitor | Hypertension | Phase IIa data showed it caused clinically significant reductions in blood pressure and was well tolerated (1/8) |
| Surface Logix* | SLx-4090 | A nonsystemically available microsomal triglyceride transfer protein inhibitor | To lower cholesterol | Phase IIa data showed significant reductions in postprandial tri-glycerides and LDL cholesterol and it was well tolerated (1/29) |
| VIA Pharmaceuticals (VIAP) | FDG-PET and VIA-2291 | Positron emission tomography with fluorodeoxyglucose tracer to measure the ability of VIA-2291, a small molecule drug | Vascular inflammation | Enrolled the first patient in a Phase II trial (1/7) |
| CENTRAL NERVOUS SYSTEM | ||||
| Catalyst Pharmaceutical Partners Inc. (CPRX) | CPP-109 | An oral small molecule designed to inhibit psychostimulant-induced dopamine release | Cocaine addiction | Started enrolling patients in its 180-subject Phase II study (1/25) |
| Cerimon Pharmaceuticals Inc.* | Diclofenac sodium | Once-daily topical treatment; a patch designed to avoid side effects of oral paid drugs | Pain | Started two Phase II/III trials (1/16) |
| Epix Pharmaceuticals Inc. (EPIX) | PRX-03140 | 5-HT4 agonist | Alzheimer's disease | Revised Phase IIa data showed patients who received 150 mg achieved a 3.6 point improvement on the Alzheimer's Disease Assessment Scale cognitive subscale, compared to a 0.9 point worsening for placebo patients (1/16) |
| Nastech Pharmaceutical Co. (NSTK) | PYY3-36 | Nasal spray; a naturally occurring hormone | Obesity | Completed enrollment of 551 patients (1/8) |
| Orexigen Therapeutics Inc. (OREX) | Empatic | A fixed-dose combination of zonisamide sustained release and bupropion sustained release | Obesity | Phase IIb data showed weight loss through 48 weeks for those receiving 360 mg in the intent-to-treat group of 14% and 15.1% in the completer group (1/7) |
| Pipex Pharmaceuticals Inc. (AMEX:PP) | Coprexa | Tetrathiomolybdate | Alzheimer's disease | Started a Phase II trial (1/7) |
| Summit Corp. plc* (UK) | SMT D001 | A small molecule combining two off-patent drugs | Sialorrhoea | Started a Phase II trial (1/16) |
| DIABETES | ||||
| Diamyd Medical AB (Sweden; SSE:DIAMB) | Diamyd | Diabetes vaccine | Type I diabetes | Phase IIb data showed the drug preserved beta cell function for 30 months in patients with Type I diabetes (1/22) |
| Immunosyn Corp. (OTC BB: IMYN) | SF-1019 | Comprised of low molecular weight lipo-peptides; a biological response modifier | Diabetic ulcers | Completed the first phase of a proof-of-concept study (1/17) |
| Oculus Innovative Sciences Inc. (OCLS) | Microcyn | A controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology for treating pathogens | Diabetic foot ulcers | Completed patient treatment and follow-up (1/3) |
| Sangamo BioSciences Inc. (SGMO) | SB-509 | An injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein trans-cription factor designed to upregulate the vascular endothelial growth factor A gene | Mild-to-moderate diabetic neuropathy | Started a Phase II trial (1/7) |
| Trophos SA* (France) | TRO19622 | Compound believed to promote the survival of a range of neurons | Diabetic neuropathy | Completed enrollment of the first 90 patients in a Phase IIa trial (1/18) |
| INFECTION | ||||
| Alnylam Pharmaceuticals Inc. (ALNY) | ALN-RSV01 | Antiviral RNAi drug | Respiratory syncytial virus infection | Phase II data showed it was well tolerated and demonstrated statistically significant antiviral activity (1/23) |
| BioCryst Pharmaceuticals Inc. (BCRX) | Peramivir | Intramuscularly delivered | Influenza | Phase II data showed statistically significant reductions in influenza virus shedding in both active treatment groups, when compared with placebo (1/24) |
| LifeCycle Pharma AS (Denmark; CSE:LCP) | LCP-Tacro | A once-daily tablet version of tacrolimus | Autoimmune hepatitis | Initiated a Phase II trial (1/2) |
| Migenix Inc. (Canada; TSX:MGI) | Celgosivir | An oral alpha glucosidase I inhibitor | Hepatitis C virus | Company is adding a 600-mg combination therapy arm to the Phase II viral kinetics study (1/31) |
| Progenics Pharmaceuticals Inc. (PGNX) | PRO 140 | Humanized monoclonal antibody directed against CCR5 | HIV | Started a Phase II program (1/15) |
| Protherics plc (UK; PTIL; LSE:PTI) and AstraZeneca plc (UK) | CytoFab | An antitumor necrosis factor-alpha polyclonal antibody fragment | Severe sepsis | Started an expanded Phase II program (1/22) |
| Rib-X Pharmaceuticals Inc.* | RX-1741 | Oxazolidinone antibiotic | Community-acquired pneumonia | Started two Phase II trials (1/4) |
| MISCELLANEOUS | ||||
| Amicus Therapeutics Inc. (FOLD) | Plicera | Isofagamine tartrate | Gaucher disease | Phase II showed it was safe and well tolerated (1/7) |
| Inverseon Inc.* | Nadolol | Beta blocker | Asthma | Phase IIa data showed that eight of 10 patients experienced a clinically meaningful, dose-related reduction in airway hyper-responsiveness (1/29) |
| Isotechnika Inc. (Canada; TSX:ISA) | ISA247 | Immunosuppressive agent | Biopsy-proven acute rejection episodes | Enrolled the last patient in its six-month Phase IIb trial (1/3) |
| Kiadis Pharma* (the Netherlands) | Rhitol | A small-molecule drug designed to selectively accumulate in reactive immune cells and to eliminate those cells upon photo activation | Graft-vs.-host disease | The last patient completed a six- month treatment cycle in a Phase II trial (1/31) |
| LifeCycle Pharma AS (Denmark; CSE:LCP) | LCP-Tacro | Immunosuppressant | Liver transplant | Phase II data showed the drug had better availability and pharmacokinetics than Prograf (1/18) |
| Sangart Inc.* | Hemospan | A hemoglobin-based oxygen transport agent | Chronic critical limb ischemia | Started testing product in a Phase II study (1/7) |
| Tengion Inc.* | Neo-Bladder Augment |
Derived from a patient's own cells |
Non-neurogenic overactive bladder |
Started its third Phase II (1/3) |
| Tercica Inc. (TRCA) and Genentech Inc. (NYSE:DNA) | Increlex and Nutropin AQ (both FDA-approved) | Recombinant insulin-like growth factor-1 | Short stature and other metabolic disorders | Started dosing the first patient in a Phase II trial testing the combination of Genentech's Nutropin AQ and Tercica's Increlex (1/23) |
| Theravance Inc. (THRX) and GlaxoSmithKline plc (UK) | GW685698; GW642444 | Inhaled corticosteroid; Long-acting bega agonist | Asthma | Started large Phase IIb trials (1/3) |
| Topigen Pharmaceuticals Inc.* | TPI ASM8 | Inhaled anti-inflammatory RNA-targeting drug | Asthma | Started a Phase II trial (1/29) |
| XenoPort Inc. (XNPT) | XP19986 | A transported prodrug of R-baclofen | Gastroesophageal reflux disease & spinal cord injury | Started Phase II trials (1/3) |
|
Notes: * Privately held. Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.